

Cover Story
Real-world Evidence
By Matthew Bin Han Ong
Routine screening procedures for breast, colon, and cervical cancers in the first half of 2021 have failed to recover, falling by about a third below historical baselines, even as Americans are resuming normal activities.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research
- Sakaguchi, Ramsdell, Rudensky win Crafoord Prize for discoveries in immune regulation
- Anthony Letai sworn in as 18th NCI director
- Trump backs off the 100% pharma tariffs ultimatum
- U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs - The evolution of cellular immunotherapy: From transplant to CAR T cells